Changes in lipid and carbohydrate metabolism under mTOR- and calcineurin-based immunosuppressive regimen in adult patients after liver transplantation

European Journal of Internal Medicine

Volumn 29, Issue , 2016, Pages 104-109

  Zimmermann, Anca ^a   Zobeley, Christina ^a   Weber, M M ^a   Lang, H ^a   Galle, Peter R ^a   Zimmermann, Tim ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Abbreviations LT liver transplantation; CNI calcineurin inhibitors; CsA cyclosporine; DM diabetes mellitus; Ev everolimus; HDL C HDL cholesterol; HOMA B homeostasis model assessment; HOMA IR homeostasis model assessment insulin resistance; IRI insulin resistance index; LDL C LDL cholesterol; mTOR mammalian target of rapamycin; sd LDL small dense LDL; Sir sirolimus; Tac tacrolimus; TC total cholesterol; TG triglycerides

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; RAPAMYCIN; TRIACYLGLYCEROL; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; DYSGLYCEMIA; DYSLIPIDEMIA; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; LIPID METABOLISM; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; CHEMICALLY INDUCED; CROSS-SECTIONAL STUDY; DRUG EFFECTS; GERMANY; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RISK FACTOR; YOUNG ADULT;

ADULT; AGED; CALCINEURIN INHIBITORS; CARBOHYDRATE METABOLISM; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; GERMANY; GLUCOSE TOLERANCE TEST; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TOR SERINE-THREONINE KINASES; TRIGLYCERIDES; YOUNG ADULT;

EID: 84954306260     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2015.12.022     Document Type: Article

References (27)

1. M. Berenguer, M. Prieto, F. San Juan, J.M. Rayon, F. Martinez, D. Carrasco, and et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients Hepatology 36 1 2002 202 210
2. H. Holdaas, L. Potena, and F. Saliba mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern? Transplant Rev (Orlando) 29 2 2015 93 102
3. G. Spagnoletti, F. Citterio, E. Favi, E. Rossi, F. Delreno, I. De Santis, and et al. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine Transpl Proc 41 4 2009 1175 1177
4. G. Tenderich, U. Fuchs, A. Zittermann, R. Muckelbauer, H.K. Berthold, and R. Koerfer Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients Clin Transpl 21 4 2007 536 543
5. D.O. Taylor, M.L. Barr, B. Radovancevic, D.G. Renlund, R.M. Mentzer Jr.; F.W. Smart, and et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus J Heart Lung Transplant 18 4 1999 336 345
6. A. Prokai, A. Fekete, K. Pasti, K. Rusai, N.F. Banki, G. Reusz, and et al. The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus Pediatr Diabetes 13 1 2012 81 91
7. Y. Hara, N. Kawagishi, W. Nakanichi, K. Tokodai, C. Nakanichi, S. Miyagi, and et al. Prevalence and risk factors of obesity, hypertension, dyslipidemia and diabetes mellitus before and after adult living donor liver transplantation Hepatol Res 2014 10.1111/hepr.12418 [Epub ahead of print]
8. M.J. Pereira, J. Palming, M. Rizell, M. Aureliano, E. Carvalho, M.K. Svensson, and et al. The immunosuppressive agents rapamycin, cyclosporin A and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipose tissue Mol Cell Endocrinol 365 2 2013 260 269
9. A. Siirtola, M. Antikainen, M. Ala-Houhala, A.M. Koivisto, T. Solakivi, S.M. Virtanen, and et al. Insulin resistance, LDL particle size, and LDL susceptibility to oxidation in pediatric kidney and liver recipients Kidney Int 67 5 2005 2046 2055
10. R. Chatrala, M.B. Siddiqui, R.T. Starvitz, C. Driscoll, A. Sanyal, C. Sargeant, and et al. Evolution of serum atherogenic risk in liver transplant recipients. Role of lipoproteins and metabolic and inflammatory markers Liver Transpl 21 5 2015 623 630
11. M.J. Chapman, S. Goldstein, D. Lagrange, and P.M. Laplaud A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum J Lipid Res 22 1981 339 358
12. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogenous in their interaction with the cellular LDL receptor. J Lipid Res 991; 32: 1741-53.
13. M.A. Austin, C.H. Breslow, C.H. Hennekens, J.E. Buring, W.C. Willet, and R. Krauss Low-density lipoprotein subclass patterns and risk of myocardial infarction JAMA 260 1988 1917 1921
14. B. Lamarche, A. Tchernof, S. Moorjani, B. Chantin, G.R. Dagenais, P.J. Lupien, and et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men Circulation 95 1997 69 75
15. J. Vakkilainen, G. Steiner, J.C. Ansquer, F. Aaubin, S. Rattier, C. Foucher, and et al. Relationships between LDL lipoprotein particle size, plasma lipoproteins and progression of coronary artery disease Circulation 107 2003 1733 1737
16. H. Arai, Y. Kokubo, M. Watanabe, T. Sawamura, Y. Ito, A. Minagawa, and et al. Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita Study J Atheroscler Thromb 20 2 2013 195 203
17. M.R. Lucey, N. Terrault, L. Ojo, J.E. Hay, J. Neuberger, E. Blumberg, and et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation Liver Transpl 19 2013 3 26
18. J.J. Davidson, A.A. Wilkinson, J.J. Dantal, F.F. Dotta, H.H. Haller, D.D. Hernández, and et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. In: proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003 Transplantation 75 2003 3 24
19. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, and et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 55 2012 1577 1596
20. H.C. Geiss, S. Bremer, P.H.R. Barrett, C. Otto, and K.G. Parhofer In vivo metabolism of LDL subfractions in patients with homozygous FH on statin therapy: rebound analysis of LDL subfractions after LDL apheresis J Lipid Res 45 2004 1459 1467
21. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner Homeostasis model assessment: insulin resistance and ß-cells function from fasting plasma glucose and insulin concentration in men Diabetologia 28 1985 412 419
22. L.U. Monzillo, and H. Osama Evaluation of insulin sensitivity in clinical practice and in research settings Nutr Rev 61 2003 397 412
23. S. Badiou, V. Garrique, A.M. Dupuy, G. Chong, J.P. Cristol, and G. Mourad Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications? Transpl Proc 38 7 2006 2314 2316
24. D.N. Perrea, K.G. Moulakakis, M.V. Poulakou, I.S. Vlachos, N. Nikiteas, and A. Kostakis Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function Int Urol Nephrol 40 2 2008 521 527
25. K. Claes, H.U. Meier-Kriesche, J.D. Schold, Y. Vanrenterghem, P.F. Halloran, and H. Ekberg Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study Nephrol Dial Transplant 27 2 2012 Feb 850 857
26. H.M. Lai, R. Pawar, D.C. Wolf, and W.S. Aronow Impact of cardiovascular risk factors on long-term mortality after liver transplantation Am Heart Ther 2014 [epub ahead of print]
27. M.S. Tong, H.T. Chai, W.H. Liu, C.L. Chen, M. Fu, Y.H. Lin, and et al. Prevalance of hypertension after living-donor liver transplantation: a prospective study Transplant Proc 47 2 2015 445 450